Literature DB >> 8097999

Diagnostic value of proliferating cell nuclear antigen for myogenic tumors of the stomach.

T Oyama1, H Watanabe, M Iwafuchi, T Maejima, Y Ajioka.   

Abstract

The histological diagnosis of gastric leiomyosarcoma and the grading of its malignancy are based on anaplasia, mitotic counts, cellularity, etc, but generally are subjective. To establish more objective criteria, a monoclonal antibody to proliferating cell nuclear antigen (PCNA), PC10, which is a marker for proliferative activity of tumors, was applied to 21 myogenic tumors of the stomach (14 leiomyomas and 7 leiomyosarcomas) fixed in formalin. The reaction-time (1-4 minutes) for the staining was decided section by section, under direct observation of its inner controls. The PCNA labeling index of the proliferative zone of the normal fundic gland in each tumor-containing section showed no significant difference among three groups with different formalin fixation times (5 cases fixed 3 days or less, 10 cases fixed 4-10 days and 6 cases fixed 11 days or more), when their inner controls stained well. The PCNA labeling index of 7 leiomyosarcomas was higher than that of 14 leiomyomas (P < 0.01), and correlated well with the mitotic index (r = 0.98). An 8 mm cellular leiomyoma revealed a PCNA labeling index as high as that of low-grade leiomyosarcoma. It is concluded that PCNA staining is a useful indicator to distinguish leiomyosarcoma from leiomyoma and grade the malignancy of leiomyosarcoma, and that small leiomyosarcoma may be diagnosed as cellular leiomyoma in hematoxylin-eosin stained sections, because of low grade atypia in the early phase.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8097999     DOI: 10.1007/bf02779220

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  8 in total

1.  PCNA staining and its problems in gastrointestinal tract.

Authors:  N Kato; H Watanabe; M Sato; Y Oohashi
Journal:  Gastroenterol Jpn       Date:  1992-08

2.  Prognostic value of proliferating cell nuclear antigen in gastric carcinoma.

Authors:  S Jain; M I Filipe; P A Hall; N Waseem; D P Lane; D A Levison
Journal:  J Clin Pathol       Date:  1991-08       Impact factor: 3.411

3.  Nucleolar organizer regions in myogenic stromal tumours of the stomach.

Authors:  H P Sinn; T Lehnert; C Kandetzki; R Waldherr
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

4.  Smooth muscle tumors of the gastrointestinal tract. A study of 56 cases followed for a minimum of 10 years.

Authors:  H L Evans
Journal:  Cancer       Date:  1985-11-01       Impact factor: 6.860

5.  Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms.

Authors:  P A Hall; D A Levison; A L Woods; C C Yu; D B Kellock; J A Watkins; D M Barnes; C E Gillett; R Camplejohn; R Dover
Journal:  J Pathol       Date:  1990-12       Impact factor: 7.996

6.  A comparison of proliferating cell nuclear antigen (PCNA) immunostaining, nucleolar organizer region (AgNOR) staining, and histological grading in gastrointestinal stromal tumours.

Authors:  C C Yu; C D Fletcher; P L Newman; J R Goodlad; J C Burton; D A Levison
Journal:  J Pathol       Date:  1992-02       Impact factor: 7.996

7.  Myosarcomas of the stomach: natural history, prognostic factors and management.

Authors:  M H Shiu; G H Farr; D N Papachristou; S I Hajdu
Journal:  Cancer       Date:  1982-01-01       Impact factor: 6.860

8.  Smooth muscle tumors of the gastrointestinal tract. Flow cytometric quantitation of DNA and nuclear antigen content and correlation with histologic grade.

Authors:  M T Kiyabu; P C Bishop; J W Parker; R R Turner; P L Fitzgibbons
Journal:  Am J Surg Pathol       Date:  1988-12       Impact factor: 6.394

  8 in total
  1 in total

1.  Enhanced proliferation and differentiation of HO-1 gene-modified bone marrow-derived mesenchymal stem cells in the acute injured kidney.

Authors:  Nanmei Liu; Huiling Wang; Guofeng Han; Jin Cheng; Weifeng Hu; Jinyuan Zhang
Journal:  Int J Mol Med       Date:  2018-05-11       Impact factor: 4.101

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.